Regorafenib -- Benefit Assessment According to §35a Social Code Book V [Internet].

Background In accordance with § 35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug regorafenib. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as "the company"). The dossier was sent to IQWiG on 1 October 2015.

http://ift.tt/2za9van